TNKase will be available for the treatment of acute ischemic stroke in adults, joining the Roche subsidiary’s Activase (alteplase) on the market – also approved for the same indication.

TNKase is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration compared to the standard-of-care, Activase, which is administered as an IV bolus followed by ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed ...

The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, ...